Edgewise Therapeutics Inc (NAS:EWTX)

$ 28.74 -0.92 (-3.1%) Market Cap: 2.72 Bil Enterprise Value: 2.32 Bil PE Ratio: 0 PB Ratio: 5.55 GF Score: 35/100

Edgewise Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 09, 2024
Edgewise Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript
Jun 13, 2023
Edgewise Therapeutics Inc at Bank of America Global Healthcare Conference Transcript
May 09, 2023
Edgewise Therapeutics Inc at Stifel CNS Days (Virtual) Transcript
Mar 28, 2023
Edgewise Therapeutics Inc at Cowen Health Care Conference Transcript
Mar 08, 2023
Edgewise Therapeutics Inc at SVB Securities Global Biopharma Conference (Virtual) Transcript
Feb 14, 2023
Edgewise Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 10, 2023
Edgewise Therapeutics Inc at Stifel Healthcare Conference Transcript
Nov 16, 2022
Edgewise Therapeutics Inc at Goldman Sachs Global Healthcare Conference Transcript
Jun 15, 2022
Edgewise Therapeutics Inc at Bank of America Healthcare Conference Transcript
May 10, 2022
Edgewise Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 10, 2022
Edgewise Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 09, 2021

Edgewise Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 09, 2024 / 06:30PM GMT

Release Date Price: $11.05 (+3.76%)

Transcript 8-K

Tessa Romero JPMorgan;Analyst

Welcome everyone to the 42nd Annual JPMorgan Healthcare Conference. My name is Tessa Romero, and I'm the senior biotech analyst at JPMorgan, or one of them. Our next presenting company is Edgewise Therapeutics and presenting on behalf of the company, we have CEO, Kevin Koch. Kevin?

Kevin Koch Edgewise Therapeutics

Inc. - President & CEO

Okay. Well, thank you all for coming and thanks for the invitation. It's been a great year of '23 and even better '24 for Edgewise therapeutics. Here's my forward-looking statements.

Yes. Okay. So Edgewise Therapeutics is a research and development biotech company targeting muscle for the treatment of rare unmet medical need diseases. We've had rapidly advance our drug for muscular dystrophy now in pivotal studies, EDG-5506 in Becker muscular dystrophy and additional data coming this year.

In addition, muscular dystrophy, we've also moved into clinical development, EDG-7500, which is a novel mechanism for the treatment of hypertrophic cardiomyopathy. And again, we are

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.